Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive clinical trial results in obesity in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit www.kailera.com.
Company Details
- Employees
- 121
- Founded
- 2024
- Address
- Weight Bias - The First Step In Challenging It And Advocating For More Inclusive And Equitable Environments.
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Kailera Therapeutics Questions
Kailera Therapeutics's LinkedIn profile is https://www.linkedin.com/company/kaileratx
Kailera Therapeutics has
121 employees.
View email and phone details for 121
employees at Kailera Therapeutics.
Kailera Therapeutics's industry is
Biotechnology Research
Kailera Therapeutics's top competitors are
Terray Therapeutics,
Treeline Biosciences,
City Therapeutics,
Aspect Biosystems,
Aktis Oncology,
Azurbio Pharma,
Triveni Bio,
Avencell,
Seaport Therapeutics,
Atalanta Therapeutics.
Kailera Therapeutics's categories are Biotechnology Research
Kailera Therapeutics's founding year is 2024
